PMID- 30643547
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231005
IS  - 1758-1974 (Electronic)
IS  - 1758-1966 (Print)
IS  - 1758-1966 (Linking)
VI  - 5
IP  - 1
DP  - 2016 Apr
TI  - Nintedanib in advanced NSCLC: management of adverse events.
PG  - 29-41
LID - 10.2217/lmt.15.33 [doi]
AB  - Nintedanib plus docetaxel is approved in the EU for the treatment of patients 
      with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma 
      histology after first-line chemotherapy. Nintedanib in combination with docetaxel 
      has a manageable safety profile in adenocarcinoma NSCLC patients. The most 
      frequent adverse events (AEs) associated with nintedanib are gastrointestinal 
      events and elevations in liver enzymes. Most AEs can be managed effectively with 
      supportive treatment or a dose reduction and do not require permanent 
      discontinuation. This article aims to provide practical guidance on management of 
      AEs and how patients should be assessed for AEs prior to initiation and regularly 
      monitored throughout treatment. Patients and their carers can play an important 
      role in recognizing and managing AEs and should be given the relevant 
      information, skills and confidence to achieve this.
FAU - Lemmens, Liesbeth
AU  - Lemmens L
AD  - COPE-Unlimited, Kermt-Hasselt, Belgium; Tel.: +32 0 496101965.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20151103
PL  - England
TA  - Lung Cancer Manag
JT  - Lung cancer management
JID - 101588392
PMC - PMC6322586
OTO - NOTNLM
OT  - NSCLC
OT  - adenocarcinoma
OT  - adverse events
OT  - adverse reactions
OT  - diarrhea
OT  - increased ALT
OT  - increased AST
OT  - neutropenia
OT  - nintedanib
COIS- Financial & competing interests disclosure L Lemmens is a consult for Boehringer 
      Ingelheim, Amgen and Novartis. The author has no other relevant affiliations or 
      financial involvement with any organization or entity with a financial interest 
      in or financial conflict with the subject matter or materials discussed in the 
      manuscript apart from those disclosed. Medical writing assistance was provided by 
      Huw Jones and Suzanne Patel (inVentiv Health, London, UK) during preparation of 
      this report and was supported financially by Boehringer Ingelheim.
EDAT- 2016/04/01 00:00
MHDA- 2016/04/01 00:01
PMCR- 2015/11/03
CRDT- 2019/01/16 06:00
PHST- 2019/01/16 06:00 [entrez]
PHST- 2016/04/01 00:00 [pubmed]
PHST- 2016/04/01 00:01 [medline]
PHST- 2015/11/03 00:00 [pmc-release]
AID - 10.2217/lmt.15.33 [doi]
PST - ppublish
SO  - Lung Cancer Manag. 2016 Apr;5(1):29-41. doi: 10.2217/lmt.15.33. Epub 2015 Nov 3.